Followers | 36 |
Posts | 3647 |
Boards Moderated | 0 |
Alias Born | 07/08/2002 |
Friday, November 18, 2022 8:43:46 AM
If you're interested at all:
https://www.mdpi.com/1422-0067/23/22/14159/htm
Published yesterday (excerpt): Belonging to a different pharmacological family, Leronlimab is a humanized igG4k monoclonal antibody also able to bind CCR5. Adams et al. [69] recently reported some clinical trials testing Leronlimab in metastatic TNBC patients. The phase 1b/2 dose escalation (NCT03838367), Compassionate Use (NCT04313075) and the Basket Study (NCT04504942) were pooled in order to evaluate the drug’s safety and efficacy at 12 months. After the analysis of 28 metastatic TNBC patients, the authors showed that Leronlimab has significant antitumor activity. The clinical trials suggest that metastatic TNBC patients dosed with Leronlimab have a real clinical benefit with improved 1-year progression-free and overall survival and few treatment-emergent adverse events. Finally, after exploring the effect of Leronlimab on circulating tumor-associated cells (TACs) from peripheral blood, the authors revealed that Leronlimab resulted in a drop in circulating TACs in the majority of patients correlating with early therapy response.
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM